|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:TRA2B-LEPREL1 (FusionGDB2 ID:92966) |
Fusion Gene Summary for TRA2B-LEPREL1 |
Fusion gene summary |
Fusion gene information | Fusion gene name: TRA2B-LEPREL1 | Fusion gene ID: 92966 | Hgene | Tgene | Gene symbol | TRA2B | LEPREL1 | Gene ID | 6434 | 55214 |
Gene name | transformer 2 beta homolog | prolyl 3-hydroxylase 2 | |
Synonyms | Htra2-beta|PPP1R156|SFRS10|SRFS10|TRA2-BETA|TRAN2B | LEPREL1|MCVD|MLAT4 | |
Cytomap | 3q27.2 | 3q28 | |
Type of gene | protein-coding | protein-coding | |
Description | transformer-2 protein homolog betaTRA-2 betaprotein phosphatase 1, regulatory subunit 156splicing factor, arginine/serine-rich 10 (transformer 2 homolog, Drosophila)transformer-2 protein homolog B | prolyl 3-hydroxylase 2leprecan-like 1myxoid liposarcoma-associated protein 4procollagen-proline 3-dioxygenase 2prolyl 3-hydroxylase 3 | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | . | . | |
Ensembl transtripts involved in fusion gene | ENST00000453386, ENST00000382191, ENST00000471134, ENST00000342294, | ENST00000319332, ENST00000427335, | |
Fusion gene scores | * DoF score | 14 X 9 X 8=1008 | 5 X 3 X 5=75 |
# samples | 15 | 6 | |
** MAII score | log2(15/1008*10)=-2.74846123300404 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(6/75*10)=-0.321928094887362 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: TRA2B [Title/Abstract] AND LEPREL1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | TRA2B(185655613)-LEPREL1(189681887), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | TRA2B | GO:0000381 | regulation of alternative mRNA splicing, via spliceosome | 12165565|12761049 |
Hgene | TRA2B | GO:0000398 | mRNA splicing, via spliceosome | 9546399 |
Hgene | TRA2B | GO:0048026 | positive regulation of mRNA splicing, via spliceosome | 15009664 |
Tgene | LEPREL1 | GO:0008285 | negative regulation of cell proliferation | 19436308 |
Tgene | LEPREL1 | GO:0019511 | peptidyl-proline hydroxylation | 18487197 |
Tgene | LEPREL1 | GO:0032963 | collagen metabolic process | 18487197 |
Fusion gene breakpoints across TRA2B (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across LEPREL1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | UCS | TCGA-ND-A4WF | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - |
ChimerDB4 | UCS | TCGA-ND-A4WF | TRA2B | chr3 | 185649365 | - | LEPREL1 | chr3 | 189681887 | - |
ChimerDB4 | UCS | TCGA-ND-A4WF-01A | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - |
Top |
Fusion Gene ORF analysis for TRA2B-LEPREL1 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000453386 | ENST00000319332 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - |
In-frame | ENST00000453386 | ENST00000427335 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - |
5UTR-3CDS | ENST00000382191 | ENST00000319332 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - |
5UTR-3CDS | ENST00000382191 | ENST00000427335 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - |
intron-3CDS | ENST00000471134 | ENST00000319332 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - |
intron-3CDS | ENST00000471134 | ENST00000427335 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - |
In-frame | ENST00000342294 | ENST00000319332 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - |
In-frame | ENST00000342294 | ENST00000427335 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - |
intron-3CDS | ENST00000453386 | ENST00000319332 | TRA2B | chr3 | 185649365 | - | LEPREL1 | chr3 | 189681887 | - |
intron-3CDS | ENST00000453386 | ENST00000427335 | TRA2B | chr3 | 185649365 | - | LEPREL1 | chr3 | 189681887 | - |
intron-3CDS | ENST00000382191 | ENST00000319332 | TRA2B | chr3 | 185649365 | - | LEPREL1 | chr3 | 189681887 | - |
intron-3CDS | ENST00000382191 | ENST00000427335 | TRA2B | chr3 | 185649365 | - | LEPREL1 | chr3 | 189681887 | - |
5UTR-3CDS | ENST00000471134 | ENST00000319332 | TRA2B | chr3 | 185649365 | - | LEPREL1 | chr3 | 189681887 | - |
5UTR-3CDS | ENST00000471134 | ENST00000427335 | TRA2B | chr3 | 185649365 | - | LEPREL1 | chr3 | 189681887 | - |
intron-3CDS | ENST00000342294 | ENST00000319332 | TRA2B | chr3 | 185649365 | - | LEPREL1 | chr3 | 189681887 | - |
intron-3CDS | ENST00000342294 | ENST00000427335 | TRA2B | chr3 | 185649365 | - | LEPREL1 | chr3 | 189681887 | - |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000453386 | TRA2B | chr3 | 185655613 | - | ENST00000319332 | LEPREL1 | chr3 | 189681887 | - | 1730 | 312 | 830 | 1297 | 155 |
ENST00000453386 | TRA2B | chr3 | 185655613 | - | ENST00000427335 | LEPREL1 | chr3 | 189681887 | - | 1627 | 312 | 830 | 1297 | 155 |
ENST00000342294 | TRA2B | chr3 | 185655613 | - | ENST00000319332 | LEPREL1 | chr3 | 189681887 | - | 1607 | 189 | 707 | 1174 | 155 |
ENST00000342294 | TRA2B | chr3 | 185655613 | - | ENST00000427335 | LEPREL1 | chr3 | 189681887 | - | 1504 | 189 | 707 | 1174 | 155 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000453386 | ENST00000319332 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - | 0.87879306 | 0.12120693 |
ENST00000453386 | ENST00000427335 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - | 0.84969765 | 0.15030229 |
ENST00000342294 | ENST00000319332 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - | 0.75877553 | 0.24122442 |
ENST00000342294 | ENST00000427335 | TRA2B | chr3 | 185655613 | - | LEPREL1 | chr3 | 189681887 | - | 0.7661936 | 0.23380639 |
Top |
Fusion Genomic Features for TRA2B-LEPREL1 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for TRA2B-LEPREL1 |
Go to FGviewer for the breakpoints of chr3:185655613-chr3:189681887 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
. | . |
FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Tgene | LEPREL1 | chr3:185655613 | chr3:189681887 | ENST00000319332 | 12 | 15 | 705_708 | 631.0 | 709.0 | Motif | Prevents secretion from ER |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000342294 | - | 1 | 2 | 231_287 | 12.0 | 39.0 | Compositional bias | Note=Arg/Ser-rich (RS2 domain) |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000342294 | - | 1 | 2 | 31_113 | 12.0 | 39.0 | Compositional bias | Note=Arg/Ser-rich (RS1 domain) |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000382191 | - | 1 | 8 | 231_287 | 0 | 189.0 | Compositional bias | Note=Arg/Ser-rich (RS2 domain) |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000382191 | - | 1 | 8 | 31_113 | 0 | 189.0 | Compositional bias | Note=Arg/Ser-rich (RS1 domain) |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000453386 | - | 1 | 9 | 231_287 | 12.0 | 289.0 | Compositional bias | Note=Arg/Ser-rich (RS2 domain) |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000453386 | - | 1 | 9 | 31_113 | 12.0 | 289.0 | Compositional bias | Note=Arg/Ser-rich (RS1 domain) |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000342294 | - | 1 | 2 | 118_196 | 12.0 | 39.0 | Domain | RRM |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000382191 | - | 1 | 8 | 118_196 | 0 | 189.0 | Domain | RRM |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000453386 | - | 1 | 9 | 118_196 | 12.0 | 289.0 | Domain | RRM |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000342294 | - | 1 | 2 | 193_230 | 12.0 | 39.0 | Region | Note=Linker |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000382191 | - | 1 | 8 | 193_230 | 0 | 189.0 | Region | Note=Linker |
Hgene | TRA2B | chr3:185655613 | chr3:189681887 | ENST00000453386 | - | 1 | 9 | 193_230 | 12.0 | 289.0 | Region | Note=Linker |
Tgene | LEPREL1 | chr3:185655613 | chr3:189681887 | ENST00000319332 | 12 | 15 | 93_99 | 631.0 | 709.0 | Compositional bias | Note=Poly-Pro | |
Tgene | LEPREL1 | chr3:185655613 | chr3:189681887 | ENST00000319332 | 12 | 15 | 557_671 | 631.0 | 709.0 | Domain | Fe2OG dioxygenase | |
Tgene | LEPREL1 | chr3:185655613 | chr3:189681887 | ENST00000319332 | 12 | 15 | 148_181 | 631.0 | 709.0 | Repeat | Note=TPR 2 | |
Tgene | LEPREL1 | chr3:185655613 | chr3:189681887 | ENST00000319332 | 12 | 15 | 210_243 | 631.0 | 709.0 | Repeat | Note=TPR 3 | |
Tgene | LEPREL1 | chr3:185655613 | chr3:189681887 | ENST00000319332 | 12 | 15 | 306_339 | 631.0 | 709.0 | Repeat | Note=TPR 4 | |
Tgene | LEPREL1 | chr3:185655613 | chr3:189681887 | ENST00000319332 | 12 | 15 | 44_77 | 631.0 | 709.0 | Repeat | Note=TPR 1 |
Top |
Fusion Gene Sequence for TRA2B-LEPREL1 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>In-frame_ENST00000453386_ENST00000319332_TCGA-ND-A4WF_TRA2B_chr3_185655613_-_LEPREL1_chr3_189681887_length(transcript)=1730nt_BP=312nt GTGCGGGACGCGCTGCAGCTGGAGAGGAAAGGCAGAGCGAGGAGGGGCGAGGCCAAGAAAGCGCGCGTTTCTGGGAGGGGAGGAGCCTGG CTAAGGAGCGCCGCGTCACATCCGGTAGAGTTAGAGCCCGTGCGGAGGCGGTGCGGAGCATTTCGGCTCTGAGCGGCTGGGCGACCGGCG CGTCGTGCGGGGCTGCGGCGGAGCCTCCTTAAGGAAGGTGCAAGAGGTTGGCAGCTTCGATTGAAGCACATCGACCGGCGACAGCAGCCA GGAGTCATGAGCGACAGCGGCGAGCAGAACTACGGCGAGCGGGCCTCTATAAAACCAAAATGTGGGCGCATGATCAGCTTCTCATCTGGA GGAGAGAACCCTCATGGGGTGAAGGCAGTCACCAAGGGAAAGAGGTGTGCTGTGGCTCTGTGGTTCACCTTGGACCCACTTTATAGAGAA TTGGAGCGAATACAGGCTGATGAAGTGATTGCAATTCTGGATCAAGAACAGCAAGGGAAGCATGAACTGAATATCAACCCTAAAGATGAG CTATAAAAATGAGAAAGAATGTTCTATCAAATATTTATTTAAATTGTTAATCTTATGAGAACCTTTTTATTTTTGTACAGAGCCATGGTA TAAATTAACAGGTTAATGTCAGTCATCAGATCTTCCTTCTCTTCCTAAGGATGCTTGTGTTGCCTCAATCTATCAATCTATCTTTCTTGT TTTGGGTTGTTTTCTCTCTCTCTCTCTCTCTCTCTCTTCTTAGAGACATGGTCTAACCATGTTGTCTAGGATATAGGGCAGTGGCTATTC ACAGATGTGATGATAGCACACTGGAGCCTCAAACTCTTAGGCTCAGGCGATCCTTCAAGCCTCCCGGGGAGCTGGGACCACAGGCACGTG CCACCACACCCAGCTCTCTTTCTTGGTTTTTCATCATTTCATGTATCTATCAAAGCCCAGTTCACCTCCTCCCCCAAACACACACACACA CACACACACACACACACACACACACAATTAAGTTGCTGCAAATTCAAAAGCTTAGAGAGAATAAGCTTCTTGGTGGTGAAACTACAACTC TCACGTGTGCTCCAGTTCTAAAATTAACCTGTGCCTGGTCTCTGAAGCCCTTTCTTGCTCTGTGCCTTTCAGCCACATCCTTAGGTGCTA ACGGCCATGAGCTCCGACTCTCCAAAGTGAGCTCCACTTTGGGTCTGAGGAGCCCCTGGCAGAGTCCACGCTGCCTCAGGTATCATGGGC GTAATGATCACCCAGGCTCCGGGAGATCTCATGGATGATTACTGTATGAGACAGAGGGGACTTCAGTCTTTCCAGGGCCTTGGTGGAATT TTTGGCTCTGGTGTTTTCGCCAGACAATAAACTTACACTGGAAGCTTTGATTCACCCTCCACAGTACTCCAGAAAGGACTGTCCTATAAG TTGTACACTTTAAAAGGTCATGTAGAGGTTGTAGTAGAATGGCTTTTCACCCTGGTGACTTTGGAAGAAACTCTTGAATACTGCCTGCAT CCGGGCACCATGGCCAGGTTGCCTAGGAGTGGGGTCCACTGATGAAAAGAGGTGTTTTGTACTTACATAAGAAAAATAAATTTCTGATTG ATTTTAACCGTCATCTGCTTATATTTTGGGGGCCCCTCCTCATTGCTGCTATCCAGCACACAGATTTGTGCTTGTGTCTGATTTGTTTAA >In-frame_ENST00000453386_ENST00000319332_TCGA-ND-A4WF_TRA2B_chr3_185655613_-_LEPREL1_chr3_189681887_length(amino acids)=155AA_start in transcript=830_stop in transcript=1297 MEPQTLRLRRSFKPPGELGPQARATTPSSLSWFFIISCIYQSPVHLLPQTHTHTHTHTHTHTIKLLQIQKLRENKLLGGETTTLTCAPVL -------------------------------------------------------------- >In-frame_ENST00000453386_ENST00000427335_TCGA-ND-A4WF_TRA2B_chr3_185655613_-_LEPREL1_chr3_189681887_length(transcript)=1627nt_BP=312nt GTGCGGGACGCGCTGCAGCTGGAGAGGAAAGGCAGAGCGAGGAGGGGCGAGGCCAAGAAAGCGCGCGTTTCTGGGAGGGGAGGAGCCTGG CTAAGGAGCGCCGCGTCACATCCGGTAGAGTTAGAGCCCGTGCGGAGGCGGTGCGGAGCATTTCGGCTCTGAGCGGCTGGGCGACCGGCG CGTCGTGCGGGGCTGCGGCGGAGCCTCCTTAAGGAAGGTGCAAGAGGTTGGCAGCTTCGATTGAAGCACATCGACCGGCGACAGCAGCCA GGAGTCATGAGCGACAGCGGCGAGCAGAACTACGGCGAGCGGGCCTCTATAAAACCAAAATGTGGGCGCATGATCAGCTTCTCATCTGGA GGAGAGAACCCTCATGGGGTGAAGGCAGTCACCAAGGGAAAGAGGTGTGCTGTGGCTCTGTGGTTCACCTTGGACCCACTTTATAGAGAA TTGGAGCGAATACAGGCTGATGAAGTGATTGCAATTCTGGATCAAGAACAGCAAGGGAAGCATGAACTGAATATCAACCCTAAAGATGAG CTATAAAAATGAGAAAGAATGTTCTATCAAATATTTATTTAAATTGTTAATCTTATGAGAACCTTTTTATTTTTGTACAGAGCCATGGTA TAAATTAACAGGTTAATGTCAGTCATCAGATCTTCCTTCTCTTCCTAAGGATGCTTGTGTTGCCTCAATCTATCAATCTATCTTTCTTGT TTTGGGTTGTTTTCTCTCTCTCTCTCTCTCTCTCTCTTCTTAGAGACATGGTCTAACCATGTTGTCTAGGATATAGGGCAGTGGCTATTC ACAGATGTGATGATAGCACACTGGAGCCTCAAACTCTTAGGCTCAGGCGATCCTTCAAGCCTCCCGGGGAGCTGGGACCACAGGCACGTG CCACCACACCCAGCTCTCTTTCTTGGTTTTTCATCATTTCATGTATCTATCAAAGCCCAGTTCACCTCCTCCCCCAAACACACACACACA CACACACACACACACACACACACACAATTAAGTTGCTGCAAATTCAAAAGCTTAGAGAGAATAAGCTTCTTGGTGGTGAAACTACAACTC TCACGTGTGCTCCAGTTCTAAAATTAACCTGTGCCTGGTCTCTGAAGCCCTTTCTTGCTCTGTGCCTTTCAGCCACATCCTTAGGTGCTA ACGGCCATGAGCTCCGACTCTCCAAAGTGAGCTCCACTTTGGGTCTGAGGAGCCCCTGGCAGAGTCCACGCTGCCTCAGGTATCATGGGC GTAATGATCACCCAGGCTCCGGGAGATCTCATGGATGATTACTGTATGAGACAGAGGGGACTTCAGTCTTTCCAGGGCCTTGGTGGAATT TTTGGCTCTGGTGTTTTCGCCAGACAATAAACTTACACTGGAAGCTTTGATTCACCCTCCACAGTACTCCAGAAAGGACTGTCCTATAAG TTGTACACTTTAAAAGGTCATGTAGAGGTTGTAGTAGAATGGCTTTTCACCCTGGTGACTTTGGAAGAAACTCTTGAATACTGCCTGCAT CCGGGCACCATGGCCAGGTTGCCTAGGAGTGGGGTCCACTGATGAAAAGAGGTGTTTTGTACTTACATAAGAAAAATAAATTTCTGATTG >In-frame_ENST00000453386_ENST00000427335_TCGA-ND-A4WF_TRA2B_chr3_185655613_-_LEPREL1_chr3_189681887_length(amino acids)=155AA_start in transcript=830_stop in transcript=1297 MEPQTLRLRRSFKPPGELGPQARATTPSSLSWFFIISCIYQSPVHLLPQTHTHTHTHTHTHTIKLLQIQKLRENKLLGGETTTLTCAPVL -------------------------------------------------------------- >In-frame_ENST00000342294_ENST00000319332_TCGA-ND-A4WF_TRA2B_chr3_185655613_-_LEPREL1_chr3_189681887_length(transcript)=1607nt_BP=189nt GAGCCCGTGCGGAGGCGGTGCGGAGCATTTCGGCTCTGAGCGGCTGGGCGACCGGCGCGTCGTGCGGGGCTGCGGCGGAGCCTCCTTAAG GAAGGTGCAAGAGGTTGGCAGCTTCGATTGAAGCACATCGACCGGCGACAGCAGCCAGGAGTCATGAGCGACAGCGGCGAGCAGAACTAC GGCGAGCGGGCCTCTATAAAACCAAAATGTGGGCGCATGATCAGCTTCTCATCTGGAGGAGAGAACCCTCATGGGGTGAAGGCAGTCACC AAGGGAAAGAGGTGTGCTGTGGCTCTGTGGTTCACCTTGGACCCACTTTATAGAGAATTGGAGCGAATACAGGCTGATGAAGTGATTGCA ATTCTGGATCAAGAACAGCAAGGGAAGCATGAACTGAATATCAACCCTAAAGATGAGCTATAAAAATGAGAAAGAATGTTCTATCAAATA TTTATTTAAATTGTTAATCTTATGAGAACCTTTTTATTTTTGTACAGAGCCATGGTATAAATTAACAGGTTAATGTCAGTCATCAGATCT TCCTTCTCTTCCTAAGGATGCTTGTGTTGCCTCAATCTATCAATCTATCTTTCTTGTTTTGGGTTGTTTTCTCTCTCTCTCTCTCTCTCT CTCTTCTTAGAGACATGGTCTAACCATGTTGTCTAGGATATAGGGCAGTGGCTATTCACAGATGTGATGATAGCACACTGGAGCCTCAAA CTCTTAGGCTCAGGCGATCCTTCAAGCCTCCCGGGGAGCTGGGACCACAGGCACGTGCCACCACACCCAGCTCTCTTTCTTGGTTTTTCA TCATTTCATGTATCTATCAAAGCCCAGTTCACCTCCTCCCCCAAACACACACACACACACACACACACACACACACACACACAATTAAGT TGCTGCAAATTCAAAAGCTTAGAGAGAATAAGCTTCTTGGTGGTGAAACTACAACTCTCACGTGTGCTCCAGTTCTAAAATTAACCTGTG CCTGGTCTCTGAAGCCCTTTCTTGCTCTGTGCCTTTCAGCCACATCCTTAGGTGCTAACGGCCATGAGCTCCGACTCTCCAAAGTGAGCT CCACTTTGGGTCTGAGGAGCCCCTGGCAGAGTCCACGCTGCCTCAGGTATCATGGGCGTAATGATCACCCAGGCTCCGGGAGATCTCATG GATGATTACTGTATGAGACAGAGGGGACTTCAGTCTTTCCAGGGCCTTGGTGGAATTTTTGGCTCTGGTGTTTTCGCCAGACAATAAACT TACACTGGAAGCTTTGATTCACCCTCCACAGTACTCCAGAAAGGACTGTCCTATAAGTTGTACACTTTAAAAGGTCATGTAGAGGTTGTA GTAGAATGGCTTTTCACCCTGGTGACTTTGGAAGAAACTCTTGAATACTGCCTGCATCCGGGCACCATGGCCAGGTTGCCTAGGAGTGGG GTCCACTGATGAAAAGAGGTGTTTTGTACTTACATAAGAAAAATAAATTTCTGATTGATTTTAACCGTCATCTGCTTATATTTTGGGGGC >In-frame_ENST00000342294_ENST00000319332_TCGA-ND-A4WF_TRA2B_chr3_185655613_-_LEPREL1_chr3_189681887_length(amino acids)=155AA_start in transcript=707_stop in transcript=1174 MEPQTLRLRRSFKPPGELGPQARATTPSSLSWFFIISCIYQSPVHLLPQTHTHTHTHTHTHTIKLLQIQKLRENKLLGGETTTLTCAPVL -------------------------------------------------------------- >In-frame_ENST00000342294_ENST00000427335_TCGA-ND-A4WF_TRA2B_chr3_185655613_-_LEPREL1_chr3_189681887_length(transcript)=1504nt_BP=189nt GAGCCCGTGCGGAGGCGGTGCGGAGCATTTCGGCTCTGAGCGGCTGGGCGACCGGCGCGTCGTGCGGGGCTGCGGCGGAGCCTCCTTAAG GAAGGTGCAAGAGGTTGGCAGCTTCGATTGAAGCACATCGACCGGCGACAGCAGCCAGGAGTCATGAGCGACAGCGGCGAGCAGAACTAC GGCGAGCGGGCCTCTATAAAACCAAAATGTGGGCGCATGATCAGCTTCTCATCTGGAGGAGAGAACCCTCATGGGGTGAAGGCAGTCACC AAGGGAAAGAGGTGTGCTGTGGCTCTGTGGTTCACCTTGGACCCACTTTATAGAGAATTGGAGCGAATACAGGCTGATGAAGTGATTGCA ATTCTGGATCAAGAACAGCAAGGGAAGCATGAACTGAATATCAACCCTAAAGATGAGCTATAAAAATGAGAAAGAATGTTCTATCAAATA TTTATTTAAATTGTTAATCTTATGAGAACCTTTTTATTTTTGTACAGAGCCATGGTATAAATTAACAGGTTAATGTCAGTCATCAGATCT TCCTTCTCTTCCTAAGGATGCTTGTGTTGCCTCAATCTATCAATCTATCTTTCTTGTTTTGGGTTGTTTTCTCTCTCTCTCTCTCTCTCT CTCTTCTTAGAGACATGGTCTAACCATGTTGTCTAGGATATAGGGCAGTGGCTATTCACAGATGTGATGATAGCACACTGGAGCCTCAAA CTCTTAGGCTCAGGCGATCCTTCAAGCCTCCCGGGGAGCTGGGACCACAGGCACGTGCCACCACACCCAGCTCTCTTTCTTGGTTTTTCA TCATTTCATGTATCTATCAAAGCCCAGTTCACCTCCTCCCCCAAACACACACACACACACACACACACACACACACACACACAATTAAGT TGCTGCAAATTCAAAAGCTTAGAGAGAATAAGCTTCTTGGTGGTGAAACTACAACTCTCACGTGTGCTCCAGTTCTAAAATTAACCTGTG CCTGGTCTCTGAAGCCCTTTCTTGCTCTGTGCCTTTCAGCCACATCCTTAGGTGCTAACGGCCATGAGCTCCGACTCTCCAAAGTGAGCT CCACTTTGGGTCTGAGGAGCCCCTGGCAGAGTCCACGCTGCCTCAGGTATCATGGGCGTAATGATCACCCAGGCTCCGGGAGATCTCATG GATGATTACTGTATGAGACAGAGGGGACTTCAGTCTTTCCAGGGCCTTGGTGGAATTTTTGGCTCTGGTGTTTTCGCCAGACAATAAACT TACACTGGAAGCTTTGATTCACCCTCCACAGTACTCCAGAAAGGACTGTCCTATAAGTTGTACACTTTAAAAGGTCATGTAGAGGTTGTA GTAGAATGGCTTTTCACCCTGGTGACTTTGGAAGAAACTCTTGAATACTGCCTGCATCCGGGCACCATGGCCAGGTTGCCTAGGAGTGGG >In-frame_ENST00000342294_ENST00000427335_TCGA-ND-A4WF_TRA2B_chr3_185655613_-_LEPREL1_chr3_189681887_length(amino acids)=155AA_start in transcript=707_stop in transcript=1174 MEPQTLRLRRSFKPPGELGPQARATTPSSLSWFFIISCIYQSPVHLLPQTHTHTHTHTHTHTIKLLQIQKLRENKLLGGETTTLTCAPVL -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for TRA2B-LEPREL1 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for TRA2B-LEPREL1 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for TRA2B-LEPREL1 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | TRA2B | C0038868 | Progressive supranuclear palsy | 1 | CTD_human |
Hgene | TRA2B | C4551862 | Ophthalmoplegia, Progressive Supranuclear | 1 | CTD_human |
Hgene | TRA2B | C4551863 | Supranuclear Palsy, Progressive, 1 | 1 | CTD_human |